Table Info

Table 1.

Representative combination nanomedicines to overcome stemness-associated chemoresistance

Chemopotentiator		Chemotherapeutic drug	Nanocarrier	Cancer (cell line)	Reference
CSC-eliminating agent	Sal	PTX	Micelle	Breast cancer (MCF-7)	[67]
	Sal	SN38	NP	Colon cancer (HCT-116)	[68]
	Sal	DOX	LP	Liver cancer (Huh-7)	[70]
	THZ	PTX	LP	Breast cancer (MCF-7)	[104]
Chemosensitizer	Tar	DOX	MSN	Breast cancer (MDA-MB-231)	[75]
	siABCG2 and siBCL-2	DOX	Noisome	Breast cancer (MDA-MB-231)	[80]
	CUR	PTX	NP	Breast cancer (MCF-7)	[82]
	RUB	DTX	Micelle	Prostate cancer (PC3)	[106]
Self-renewal inhibitor	siNotch1	Pt	Micelle	Liver cancer (SMMC7721)	[86]
	siBmi1	UA	LP	Epidermoid cancer (KB)	[87]
	Wnt and uPAR peptides	DOX	NP	Breast cancer (MDA-MB-231)	[88]
Differentiation-inducing agent	ATRA	DOX	NP	Breast cancer (MDA-MB-231)	[94]
	ATRA	DTX	Dendrisome	Breast cancer (MCF-7 and SK-BR-3)	[95]
	ATRA	IRI	NP	Breast cancer (4T1)	[96]
	ATRA	CPT	NP	Breast cancer (MCF-7)	[110]
	ATRA	DOX	NP	Breast cancer (4T1)	[111]

Tar: tariquidar; siABCG2: small interfering RNA (siRNA) targeting ABC subfamily G member 2; siBCL-2: siRNA targeting B-cell lymphoma-2; siNotch1: siRNA targeting Notch receptor 1; siBmi1: siRNA targeting BMI1 proto-oncogene, polycomb ring finger; uPAR: urokinase plasminogen activator receptor; PTX: paclitaxel; IRI: irinotecan; CPT: camptothecin; MSN: mesoporous silica NP; RUB: rubone; UA: ursolic acid; Pt: platinum; THZ: thioridazine; SN38: 7-ethyl-10-hydroxycamptothecin; Wnt: Wnt/β-catenin signaling

Declarations

Author contributions

HL: Conceptualization, Investigation, Writing—original draft, Writing—review & editing, Validation. ML and YZ: Writing—review & editing. RM: Conceptualization, Writing—original draft, Writing—review & editing, Validation, Supervision. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

This work was supported by the National Natural Science Foundation of China [82273876, 81971730, 81673381]; the Fok Ying-Tong Education Foundation for Young Teachers in the Higher Education Institutions of China [171028]; the Project of State Key Laboratory of Natural Medicines of China Pharmaceutical University [SKLNMZZ202024]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:233–54. [DOI] [PubMed]

Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14:611–29. [DOI] [PubMed] [PMC]

Huang T, Song X, Xu D, Tiek D, Goenka A, Wu B, et al. Stem cell programs in cancer initiation, progression, and therapy resistance. Theranostics. 2020;10:8721–43. [DOI] [PubMed] [PMC]

Bayik D, Lathia JD. Cancer stem cell-immune cell crosstalk in tumour progression. Nat Rev Cancer. 2021;21:526–36. [DOI] [PubMed] [PMC]

Lytle NK, Barber AG, Reya T. Stem cell fate in cancer growth, progression and therapy resistance. Nat Rev Cancer. 2018;18:669–80. [DOI] [PubMed] [PMC]

Garcia-Mayea Y, Mir C, Masson F, Paciucci R, LLeonart ME. Insights into new mechanisms and models of cancer stem cell multidrug resistance. Semin Cancer Biol. 2020;60:166–80. [DOI] [PubMed]

Vitale I, Manic G, De Maria R, Kroemer G, Galluzzi L. DNA damage in stem cells. Mol Cell. 2017;66:306–19. [DOI] [PubMed]

Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S, et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell. 2010;140:62–73. [DOI] [PubMed]

Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008;15:504–14. [DOI] [PubMed]

10.

Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44⁺ CD24⁻ prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer. 2008;98:756–65. [DOI] [PubMed] [PMC]

11.

Najafi M, Farhood B, Mortezaee K. Cancer stem cells (CSCs) in cancer progression and therapy. J Cell Physiol. 2019;234:8381–95. [DOI] [PubMed]

12.

Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020;5:8. [DOI] [PubMed] [PMC]

13.

Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CLL, Rich JN. Cancer stem cells in glioblastoma. Genes Dev. 2015;29:1203–17. [DOI] [PubMed] [PMC]

14.

Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275–84. [DOI] [PubMed]

15.

Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23:1124–34. [DOI] [PubMed]

16.

Jones CL, Inguva A, Jordan CT. Targeting energy metabolism in cancer stem cells: progress and challenges in leukemia and solid tumors. Cell Stem Cell. 2021;28:378–93. [DOI] [PubMed] [PMC]

17.

Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983–8. [DOI] [PubMed] [PMC]

18.

Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, et al. Stem cell-related “self-renewal” signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol. 2008;26:3015–24. [DOI] [PubMed]

19.

de Sousa e Melo F, Kurtova AV, Harnoss JM, Kljavin N, Hoeck JD, Hung J, et al. A distinct role for Lgr5⁺ stem cells in primary and metastatic colon cancer. Nature. 2017;543:676–80. [DOI] [PubMed]

20.

Lee CJ, Dosch J, Simeone DM. Pancreatic cancer stem cells. J Clin Oncol. 2008;26:2806–12. [DOI] [PubMed]

21.

Lawson DA, Witte ON. Stem cells in prostate cancer initiation and progression. J Clin Invest. 2007;117:2044–50. [DOI] [PubMed] [PMC]

22.

Peacock CD, Watkins DN. Cancer stem cells and the ontogeny of lung cancer. J Clin Oncol. 2008;26:2883–9. [DOI] [PubMed] [PMC]

23.

Lee TKW, Guan XY, Ma S. Cancer stem cells in hepatocellular carcinoma — from origin to clinical implications. Nat Rev Gastroenterol Hepatol. 2022;19:26–44. [DOI] [PubMed]

24.

Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, et al. Identification of cells initiating human melanomas. Nature. 2008;451:345–9. [DOI] [PubMed] [PMC]

25.

Mokhtarzadeh A, Hassanpour S, Vahid ZF, Hejazi M, Hashemi M, Ranjbari J, et al. Nano-delivery system targeting to cancer stem cell cluster of differentiation biomarkers. J Control Release. 2017;266:166–86. [DOI] [PubMed]

26.

Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5:219–34. [DOI] [PubMed]

27.

Clara JA, Monge C, Yang Y, Takebe N. Targeting signalling pathways and the immune microenvironment of cancer stem cells — a clinical update. Nat Rev Clin Oncol. 2020;17:204–32. [DOI] [PubMed]

28.

de Thé H. Differentiation therapy revisited. Nat Rev Cancer. 2018;18:117–27. [DOI] [PubMed]

29.

Dicko A, Mayer LD, Tardi PG. Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo. Expert Opin Drug Deliv. 2010;7:1329–41. [DOI] [PubMed]

30.

Ramsay EC, Santos ND, Dragowska WH, Laskin JJ, Bally MB. The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations. Curr Drug Deliv. 2005;2:341–51. [DOI] [PubMed]

31.

Shim G, Kim MG, Kim D, Park JY, Oh YK. Nanoformulation-based sequential combination cancer therapy. Adv Drug Deliv Rev. 2017;115:57–81. [DOI] [PubMed]

32.

Min J, Braatz RD, Hammond PT. Tunable staged release of therapeutics from layer-by-layer coatings with clay interlayer barrier. Biomaterials. 2014;35:2507–17. [DOI] [PubMed] [PMC]

33.

Sengupta S, Eavarone D, Capila I, Zhao G, Watson N, Kiziltepe T, et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature. 2005;436:568–72. [DOI] [PubMed]

34.

Xie F, Wang M, Chen Q, Chi T, Zhu S, Wei P, et al. Endogenous stimuli-responsive nanoparticles for cancer therapy: from bench to bedside. Pharmacol Res. 2022;186:106522. [DOI] [PubMed]

35.

Mo R, Gu Z. Tumor microenvironment and intracellular signal-activated nanomaterials for anticancer drug delivery. Mater Today Bio. 2016;19:274–83. [DOI]

36.

Lu Y, Aimetti AA, Langer R, Gu Z. Bioresponsive materials. Nat Rev Mater. 2016;2:16075. [DOI]

37.

Mi P, Cabral H, Kataoka K. Ligand-installed nanocarriers toward precision therapy. Adv Mater. 2020;32:1902604. [DOI] [PubMed]

38.

Shen S, Xia JX, Wang J. Nanomedicine-mediated cancer stem cell therapy. Biomaterials. 2016;74:1–18. [DOI] [PubMed]

39.

D’Andrea V, Panarese A, Tonda M, Biffoni M, Monti M. Cancer stem cells as functional biomarkers. Cancer Biomark. 2017;20:231–4. [DOI] [PubMed]

40.

Duan H, Liu Y, Gao Z, Huang W. Recent advances in drug delivery systems for targeting cancer stem cells. Acta Pharm Sin B. 2021;11:55–70. [DOI] [PubMed] [PMC]

41.

Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer. 2004;4:528–39. [DOI] [PubMed]

42.

Götte M, Yip GW. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res. 2006;66:10233–7. [DOI] [PubMed]

43.

Choi KY, Han HS, Lee ES, Shin JM, Almquist BD, Lee DS, et al. Hyaluronic acid-based activatable nanomaterials for stimuli-responsive imaging and therapeutics: beyond CD44-mediated drug delivery. Adv Mater. 2019;31:1803549. [DOI] [PubMed]

44.

Dzobo K, Sinkala M. Cancer stem cell marker CD44 plays multiple key roles in human cancers: immune suppression/evasion, drug resistance, epithelial-mesenchymal transition, and metastasis. OMICS. 2021;25:313–32. [DOI] [PubMed]

45.

Jafari Malek S, Khoshchehreh R, Goodarzi N, Khoshayand MR, Amini M, Atyabi F, et al. cis-dichlorodiamminoplatinum (II) glyconanoparticles by drug-induced ionic gelation technique targeted to prostate cancer: preparation, optimization and in vitro characterization. Colloids Surf B Biointerfaces. 2014;122:350–8. [DOI] [PubMed]

46.

Kesharwani P, Banerjee S, Padhye S, Sarkar FH, Iyer AK. Hyaluronic acid engineered nanomicelles loaded with 3,4-difluorobenzylidene curcumin for targeted killing of CD44+ stem-like pancreatic cancer cells. Biomacromolecules. 2015;16:3042–53. [DOI] [PubMed]

47.

Rao W, Wang H, Han J, Zhao S, Dumbleton J, Agarwal P, et al. Chitosan-decorated doxorubicin-encapsulated nanoparticle targets and eliminates tumor reinitiating cancer stem-like cells. ACS Nano. 2015;9:5725–40. [DOI] [PubMed]

48.

Kuo YC, Wang LJ, Rajesh R. Targeting human brain cancer stem cells by curcumin-loaded nanoparticles grafted with anti-aldehyde dehydrogenase and sialic acid: colocalization of ALDH and CD44. Mater Sci Eng C Mater Biol Appl. 2019;102:362–72. [DOI] [PubMed]

49.

Cho JH, Kim AR, Kim SH, Lee SJ, Chung H, Yoon MY. Development of a novel imaging agent using peptide-coated gold nanoparticles toward brain glioma stem cell marker CD133. Acta Biomater. 2017;47:182–92. [DOI] [PubMed]

50.

Kim JS, Shin DH, Kim JS. Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells. J Control Release. 2018;269:245–57. [DOI] [PubMed]

51.

Chen H, Lin J, Shan Y, Zhengmao L. The promotion of nanoparticle delivery to two populations of gastric cancer stem cells by CD133 and CD44 antibodies. Biomed Pharmacother. 2019;115:108857. [DOI] [PubMed]

52.

Zhu G, Chen X. Aptamer-based targeted therapy. Adv Drug Deliv Rev. 2018;134:65–78. [DOI] [PubMed] [PMC]

53.

He F, Wen N, Xiao D, Yan J, Xiong H, Cai S, et al. Aptamer-based targeted drug delivery systems: current potential and challenges. Curr Med Chem. 2020;27:2189–219. [DOI] [PubMed]

54.

Zeng YB, Yu ZC, He YN, Zhang T, Du LB, Dong YM, et al. Salinomycin-loaded lipid-polymer nanoparticles with anti-CD20 aptamers selectively suppress human CD20+ melanoma stem cells. Acta Pharmacol Sin. 2018;39:261–74. Erratum in: Acta Pharmacol Sin. 2018;39:330. [DOI] [PubMed] [PMC]

55.

Kim DM, Kim M, Park HB, Kim KS, Kim DE. Anti-MUC1/CD44 dual-aptamer-conjugated liposomes for cotargeting breast cancer cells and cancer stem cells. ACS Appl Bio Mater. 2019;2:4622–33. [DOI] [PubMed]

56.

Yin W, Pham CV, Wang T, Al Shamaileh H, Chowdhury R, Patel S, et al. Inhibition of autophagy promotes the elimination of liver cancer stem cells by CD133 aptamer-targeted delivery of doxorubicin. Biomolecules. 2022;12:1623. [DOI] [PubMed] [PMC]

57.

Zhou BBS, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov. 2009;8:806–23. [DOI] [PubMed]

58.

Zhang Z, Deng Q, Xiao C, Li Z, Yang X. Rational design of nanotherapeutics based on the five features principle for potent elimination of cancer stem cells. Acc Chem Res. 2022;55:526–36. [DOI] [PubMed]

59.

Zinzi L, Contino M, Cantore M, Capparelli E, Leopoldo M, Colabufo NA. ABC transporters in CSCs membranes as a novel target for treating tumor relapse. Front Pharmacol. 2014;5:163. [DOI] [PubMed] [PMC]

60.

Fulda S. Regulation of apoptosis pathways in cancer stem cells. Cancer Lett. 2013;338:168–73. [DOI] [PubMed]

61.

Shi X, Zhang Y, Zheng J, Pan J. Reactive oxygen species in cancer stem cells. Antioxid Redox Signal. 2012;16:1215–28. [DOI] [PubMed] [PMC]

62.

Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009;458:780–3. [DOI] [PubMed] [PMC]

63.

Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell. 2011;146:633–44. [DOI] [PubMed]

64.

Antoszczak M. A comprehensive review of salinomycin derivatives as potent anticancer and anti-CSCs agents. Eur J Med Chem. 2019;166:48–64. [DOI] [PubMed]

65.

Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009;138:645–59. [DOI] [PubMed] [PMC]

66.

Qi D, Liu Y, Li J, Huang JH, Hu X, Wu E. Salinomycin as a potent anticancer stem cell agent: state of the art and future directions. Med Res Rev. 2022;42:1037–63. [DOI] [PubMed] [PMC]

67.

Zhang Y, Zhang H, Wang X, Wang J, Zhang X, Zhang Q. The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles. Biomaterials. 2012;33:679–91. [DOI] [PubMed]

68.

Tsakiris N, Fauvet F, Ruby S, Puisieux A, Paquot A, Muccioli GG, et al. Combined nanomedicines targeting colorectal cancer stem cells and cancer cells. J Control Release. 2020;326:387–95. [DOI] [PubMed]

69.

Gao J, Liu J, Xie F, Lu Y, Yin C, Shen X. Co-delivery of docetaxel and salinomycin to target both breast cancer cells and stem cells by PLGA/TPGS nanoparticles. Int J Nanomedicine. 2019;14:9199–216. [DOI] [PubMed] [PMC]

70.

Wang Z, Sun M, Li W, Fan L, Zhou Y, Hu Z. A novel CD133- and EpCAM-targeted liposome with redox-responsive properties capable of synergistically eliminating liver cancer stem cells. Front Chem. 2020;8:649. [DOI] [PubMed] [PMC]

71.

Singh AK, Verma A, Singh A, Arya RK, Maheshwari S, Chaturvedi P, et al. Salinomycin inhibits epigenetic modulator EZH2 to enhance death receptors in colon cancer stem cells. Epigenetics. 2021;16:144–61. [DOI] [PubMed] [PMC]

72.

Stöhr D, Schmid JO, Beigl TB, Mack A, Maichl DS, Cao K, et al. Stress-induced TRAILR2 expression overcomes TRAIL resistance in cancer cell spheroids. Cell Death Differ. 2020;27:3037–52. [DOI] [PubMed] [PMC]

73.

Shen S, Lin S, Chen Y, Zhang Y, He Y, Xu X, et al. Combating cancer stem-like cell-derived resistance to anticancer protein by liposome-mediated acclimatization strategy. Nano Lett. 2022;22:2419–28. [DOI] [PubMed]

74.

Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. 2018;18:452–64. [DOI] [PubMed] [PMC]

75.

Pan Y, Zhou S, Li Y, Parshad B, Li W, Haag R. Novel dendritic polyglycerol-conjugated, mesoporous silica-based targeting nanocarriers for co-delivery of doxorubicin and tariquidar to overcome multidrug resistance in breast cancer stem cells. J Control Release. 2021;330:1106–17. [DOI] [PubMed]

76.

Fox E, Bates SE. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther. 2007;7:447–59. [DOI] [PubMed]

77.

Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15:49–63. [DOI] [PubMed]

78.

Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, et al. Analysis of gene expression and chemoresistance of CD133⁺ cancer stem cells in glioblastoma. Mol Cancer. 2006;5:67. [DOI] [PubMed] [PMC]

79.

Madjd Z, Mehrjerdi AZ, Sharifi AM, Molanaei S, Shahzadi SZ, Asadi-Lari M. CD44+ cancer cells express higher levels of the anti-apoptotic protein Bcl-2 in breast tumours. Cancer Immun. 2009;9:4. [PubMed] [PMC]

80.

Sun M, Yang C, Zheng J, Wang M, Chen M, Le DQS, et al. Enhanced efficacy of chemotherapy for breast cancer stem cells by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense. Acta Biomater. 2015;28:171–82. [DOI] [PubMed]

81.

Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29:212–26. [DOI] [PubMed]

82.

Yang Z, Sun N, Cheng R, Zhao C, Liu J, Tian Z. Hybrid nanoparticles coated with hyaluronic acid lipoid for targeted co-delivery of paclitaxel and curcumin to synergistically eliminate breast cancer stem cells. J Mater Chem B. 2017;5:6762–75. [DOI] [PubMed]

83.

Zhao Y, Wang K, Zheng Y, Zeng X, Lim YC, Liu T. Co-delivery of salinomycin and curcumin for cancer stem cell treatment by inhibition of cell proliferation, cell cycle arrest, and epithelial-mesenchymal transition. Front Chem. 2021;8:601649. [DOI] [PubMed] [PMC]

84.

Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, et al. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol. 2015;12:445–64. [DOI] [PubMed] [PMC]

85.

Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434:843–50. [DOI] [PubMed]

86.

Shen S, Sun CY, Du XJ, Li HJ, Liu Y, Xia JX, et al. Co-delivery of platinum drug and siNotch1 with micelleplex for enhanced hepatocellular carcinoma therapy. Biomaterials. 2015;70:71–83. [DOI] [PubMed]

87.

Li W, Yan R, Liu Y, He C, Zhang X, Lu Y, et al. Co-delivery of Bmi1 small interfering RNA with ursolic acid by folate receptor-targeted cationic liposomes enhances anti-tumor activity of ursolic acid in vitro and in vivo. Drug Deliv. 2019;26:794–802. [DOI] [PubMed] [PMC]

88.

Miller-Kleinhenz J, Guo X, Qian W, Zhou H, Bozeman EN, Zhu L, et al. Dual-targeting Wnt and uPA receptors using peptide conjugated ultra-small nanoparticle drug carriers inhibited cancer stem-cell phenotype in chemo-resistant breast cancer. Biomaterials. 2018;152:47–62. [DOI] [PubMed] [PMC]

89.

Yang R, Mondal G, Wen D, Mahato RI. Combination therapy of paclitaxel and cyclopamine polymer-drug conjugates to treat advanced prostate cancer. Nanomedicine. 2017;13:391–401. [DOI] [PubMed]

90.

Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al.; Gruppo Italiano Malattie Ematologiche dell’Adulto; the German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369:111–21. [DOI] [PubMed]

91.

Wu MJ, Kim MR, Chen YS, Yang JY, Chang CJ. Retinoic acid directs breast cancer cell state changes through regulation of TET2-PKCζ pathway. Oncogene. 2017;36:3193–206. Erratum in: Oncogene. 2023;42:1049. [DOI] [PubMed] [PMC]

92.

Wei S, Kozono S, Kats L, Nechama M, Li W, Guarnerio J, et al. Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer. Nat Med. 2015;21:457–66. [DOI] [PubMed] [PMC]

93.

David KA, Mongan NP, Smith C, Gudas LJ, Nanus DM. Phase I trial of ATRA-IV and Depakote in patients with advanced solid tumor malignancies. Cancer Biol Ther. 2010;9:678–84. [DOI] [PubMed] [PMC]

94.

Sun R, Liu Y, Li SY, Shen S, Du XJ, Xu CF, et al. Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells. Biomaterials. 2015;37:405–14. Erratum in: Biomaterials. 2020;263:120373. [DOI] [PubMed]

95.

Mu LM, Liu L, Liu R, Duan JL, Ma S, Li XQ, et al. Development of functional dendrisomes based on a single molecule of polyesterbenzylether dendrimer and their application in cancer stem cell therapy. NPG Asia Mater. 2019;11:34. [DOI]

96.

Xie X, Jiang K, Li B, Hou S, Tang H, Shao B, et al. A small-molecule self-assembled nanodrug for combination therapy of photothermal-differentiation-chemotherapy of breast cancer stem cells. Biomaterials. 2022;286:121598. [DOI] [PubMed]

97.

Shamsian A, Sepand MR, Javaheri Kachousangi M, Dara T, Ostad SN, Atyabi F, et al. Targeting tumorigenicity of breast cancer stem cells using SAHA/Wnt-b catenin antagonist loaded onto protein corona of gold nanoparticles. Int J Nanomedicine. 2020;15:4063–78. [DOI] [PubMed] [PMC]

98.

Theocharis AD, Skandalis SS, Gialeli C, Karamanos NK. Extracellular matrix structure. Adv Drug Deliv Rev. 2016;97:4–27. [DOI] [PubMed]

99.

DuFort CC, DelGiorno KE, Hingorani SR. Mounting pressure in the microenvironment: fluids, solids, and cells in pancreatic ductal adenocarcinoma. Gastroenterology. 2016;150:1545–57.e2. [DOI] [PubMed] [PMC]

100.

Najafi M, Farhood B, Mortezaee K, Kharazinejad E, Majidpoor J, Ahadi R. Hypoxia in solid tumors: a key promoter of cancer stem cell (CSC) resistance. J Cancer Res Clin Oncol. 2020;146:19–31. [DOI] [PubMed]

101.

Adiseshaiah PP, Crist RM, Hook SS, McNeil SE. Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nat Rev Clin Oncol. 2016;13:750–65. [DOI] [PubMed]

102.

Shen S, Liu M, Li T, Lin S, Mo R. Recent progress in nanomedicine-based combination cancer therapy using a site-specific co-delivery strategy. Biomater Sci. 2017;5:1367–81. [DOI] [PubMed]

103.

Liu M, Shen S, Wen D, Li M, Li T, Chen X, et al. Hierarchical nanoassemblies-assisted combinational delivery of cytotoxic protein and antibiotic for cancer treatment. Nano Lett. 2018;18:2294–303. [DOI] [PubMed]

104.

Lang T, Liu Y, Zheng Z, Ran W, Zhai Y, Yin Q, et al. Cocktail strategy based on spatio-temporally controlled nano device improves therapy of breast cancer. Adv Mater. 2019;31:1806202. Erratum in: Adv Mater. 2019;31:1903844. [DOI] [PubMed]

105.

Wang C, Wang Q, Wang H, Li Z, Chen J, Zhang Z, et al. Hydroxyethyl starch-folic acid conjugates stabilized theranostic nanoparticles for cancer therapy. J Control Release. 2023;353:391–410. [DOI] [PubMed]

106.

Lin F, Wen D, Wang X, Mahato RI. Dual responsive micelles capable of modulating miRNA-34a to combat taxane resistance in prostate cancer. Biomaterials. 2019;192:95–108. [DOI] [PubMed]

107.

Bader AG. miR-34 – a microRNA replacement therapy is headed to the clinic. Front Genet. 2012;3:120. [DOI] [PubMed] [PMC]

108.

Liu J, Chang B, Li Q, Xu L, Liu X, Wang G, et al. Redox-responsive dual drug delivery nanosystem suppresses cancer repopulation by abrogating doxorubicin-promoted cancer stemness, metastasis, and drug resistance. Adv Sci (Weinh). 2019;6:1801987. [DOI] [PubMed] [PMC]

109.

Ren Y, Wang R, Gao L, Li K, Zhou X, Guo H, et al. Sequential co-delivery of miR-21 inhibitor followed by burst release doxorubicin using NIR-responsive hollow gold nanoparticle to enhance anticancer efficacy. J Control Release. 2016;228:74–86. [DOI] [PubMed]

110.

Shen S, Xu X, Lin S, Zhang Y, Liu H, Zhang C, et al. A nanotherapeutic strategy to overcome chemotherapeutic resistance of cancer stem-like cells. Nat Nanotechnol. 2021;16:104–13. [DOI] [PubMed]

111.

Shen S, Li T, Fan J, Shao Q, Dong H, Xu X, et al. Lipid-polymer hybrid nanoparticle with cell-distinct drug release for treatment of stemness-derived resistant tumor. Acta Pharm Sin B. 2023;13:1262–73. [DOI] [PubMed] [PMC]

112.

Kuşoğlu A, Biray Avcı Ç. Cancer stem cells: a brief review of the current status. Gene. 2019;681:80–5. [DOI] [PubMed]

113.

Keller L, Pantel K. Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nat Rev Cancer. 2019;19:553–67. [DOI] [PubMed]

114.

Letai A, Bhola P, Welm AL. Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations. Cancer Cell. 2022;40:26–35. [DOI] [PubMed] [PMC]

115.

Kozma GT, Shimizu T, Ishida T, Szebeni J. Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. Adv Drug Deliv Rev. 2020;154–5:163–75. [DOI] [PubMed]

116.

Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol. 2020;15:313–20. [DOI] [PubMed] [PMC]